# Publications Search Within Results Search Within Results search ## 130 results Show filters filter\_alt Sort by Year of PublicationAlphabetical A-Z sort ## 130 results Download 130 citations download- [BibTeX](/node/730696/export?format=bibtex) - [EndNote X3 XML](/node/730696/export?format=endnote8) - [EndNote 7 XML](/node/730696/export?format=endnote7) - [Endnote tagged](/node/730696/export?format=tagged) - [Marc](/node/730696/export?format=marc) - [PubMedId](/node/730696/export?format=pubmed_id) - [RIS](/node/730696/export?format=ris) ### 2024 Baker G, Novikov E, Zhao Z, Vallius T, Davis J, Lin J-R, Muhlich J, Mittendorf E, Santagata S, Guerriero J, et al. [Quality control for single cell analysis of high-plex tissue profiles using CyLinter](/publications/quality-control-single-cell-analysis-high-plex-tissue-profiles-using-cylinter). bioRxiv. 2024. Baker G, Novikov E, Zhao Z, Vallius T, Davis J, Lin J-R, Muhlich J, Mittendorf E, Santagata S, Guerriero J, et al. [Quality control for single cell analysis of high-plex tissue profiles using CyLinter](/publications/quality-control-single-cell-analysis-high-plex-tissue-profiles-using-cylinter). bioRxiv. 2024. Guerriero J, Lin J-R, Pastorello R, Du Z, Chen Y-A, Townsend M, Shimada K, Hughes M, Ren S, Tayob N, et al. [Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer](/publications/qualification-multiplexed-tissue-imaging-assay-and-detection-novel-patterns). NPJ Breast Cancer. 2024;10(1):2. Guerriero J, Lin J-R, Pastorello R, Du Z, Chen Y-A, Townsend M, Shimada K, Hughes M, Ren S, Tayob N, et al. [Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer](/publications/qualification-multiplexed-tissue-imaging-assay-and-detection-novel-patterns). NPJ Breast Cancer. 2024;10(1):2. Haddox C, Nathenson M, Mazzola E, Lin J-R, Baginska J, Nau A, Weirather J, Choy E, Marino-Enriquez A, Morgan J, et al. [Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates](/publications/phase-ii-study-eribulin-plus-pembrolizumab-metastatic-soft-tissue-sarcomas). Clinical Cancer Research. 2024;30(7):1281–1292. Haddox C, Nathenson M, Mazzola E, Lin J-R, Baginska J, Nau A, Weirather J, Choy E, Marino-Enriquez A, Morgan J, et al. [Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates](/publications/phase-ii-study-eribulin-plus-pembrolizumab-metastatic-soft-tissue-sarcomas). Clinical Cancer Research. 2024;30(7):1281–1292. Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Jadeja S, Murphy G, Nirmal A, Lian C, Sorger P, et al. [Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence: A Pilot Study](/publications/immune-profiling-dermatologic-adverse-events-checkpoint-blockade-using-tissue-0). The Journal of investigative dermatology. 2024:S0022–202X. Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Jadeja S, Murphy G, Nirmal A, Lian C, Sorger P, et al. [Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence: A Pilot Study](/publications/immune-profiling-dermatologic-adverse-events-checkpoint-blockade-using-tissue-0). The Journal of investigative dermatology. 2024:S0022–202X. Ricciuti B, Lamberti G, Puchala S, Mahadevan N, Lin J-R, Alessi J, Chowdhury A, Li Y, Wang X, Spurr L, et al. [Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer](/publications/genomic-and-immunophenotypic-landscape-acquired-resistance-pd-l-1-blockade). Journal of Clinical Oncology. 2024;42(11):1311–1321. Ricciuti B, Lamberti G, Puchala S, Mahadevan N, Lin J-R, Alessi J, Chowdhury A, Li Y, Wang X, Spurr L, et al. [Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer](/publications/genomic-and-immunophenotypic-landscape-acquired-resistance-pd-l-1-blockade). Journal of Clinical Oncology. 2024;42(11):1311–1321. ### 2023 Lin J-R, Wang S, Coy S, Chen Y-A, Yapp C, Tyler M, Nariya M, Heiser C, Lau K, Santagata S, et al. [Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer](/publications/multiplexed-3d-atlas-state-transitions-and-immune-interaction-colorectal). Cell. 2023;186(2):363–381. Lin J-R, Wang S, Coy S, Chen Y-A, Yapp C, Tyler M, Nariya M, Heiser C, Lau K, Santagata S, et al. [Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer](/publications/multiplexed-3d-atlas-state-transitions-and-immune-interaction-colorectal). Cell. 2023;186(2):363–381. Gaglia G, Burger M, Ritch C, Rammos D, Dai Y, Crossland G, Tavana S, Warchol S, Jaeger A, Naranjo S, et al. [Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma](/publications/lymphocyte-networks-are-dynamic-cellular-communities-immunoregulatory-0). Cancer Cell. 2023;41(5):871–886. Gaglia G, Burger M, Ritch C, Rammos D, Dai Y, Crossland G, Tavana S, Warchol S, Jaeger A, Naranjo S, et al. [Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma](/publications/lymphocyte-networks-are-dynamic-cellular-communities-immunoregulatory-0). Cancer Cell. 2023;41(5):871–886. Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Murphy G, Nirmal A, Lian C, Sorger P, LeBoeuf N. [Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence](/publications/immune-profiling-dermatologic-adverse-events-checkpoint-blockade-using-tissue). bioRxiv. 2023:2023–04. Maliga Z, Kim D, Bui A-T, Lin J-R, Dewan A, Murphy G, Nirmal A, Lian C, Sorger P, LeBoeuf N. [Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence](/publications/immune-profiling-dermatologic-adverse-events-checkpoint-blockade-using-tissue). bioRxiv. 2023:2023–04. Lecky E, Mukherji A, German R, Antonellis G, Lin J-R, Yorsz M, McQueeney K, Ryan J, Ng K, Sicinska E, et al. [Sequential apoptotic and multiplexed proteomic evaluation of single cancer cells](/publications/sequential-apoptotic-and-multiplexed-proteomic-evaluation-single-cancer-cells). Science Advances. 2023;9(25):eadg4128. Lecky E, Mukherji A, German R, Antonellis G, Lin J-R, Yorsz M, McQueeney K, Ryan J, Ng K, Sicinska E, et al. [Sequential apoptotic and multiplexed proteomic evaluation of single cancer cells](/publications/sequential-apoptotic-and-multiplexed-proteomic-evaluation-single-cancer-cells). Science Advances. 2023;9(25):eadg4128. Lin J-R, Chen Y-A, Campton D, Cooper J, Coy S, Yapp C, Tefft J, McCarty E, Ligon K, Rodig S, et al. [High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers](/publications/high-plex-immunofluorescence-imaging-and-traditional-histology-same-tissue). Nature cancer. 2023;4(7):1036–1052. Lin J-R, Chen Y-A, Campton D, Cooper J, Coy S, Yapp C, Tefft J, McCarty E, Ligon K, Rodig S, et al. [High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers](/publications/high-plex-immunofluorescence-imaging-and-traditional-histology-same-tissue). Nature cancer. 2023;4(7):1036–1052. Creason A, Egger J, Watson C, Sivagnanam S, Chin K, MacPherson K, Lin J-R, Chen Y-A, Johnson B, Feiler H, et al. [Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancers](/publications/longitudinal-and-multimodal-auditing-tumor-adaptation-cdk46-inhibitors-hr). bioRxiv. 2023:2023–09. Creason A, Egger J, Watson C, Sivagnanam S, Chin K, MacPherson K, Lin J-R, Chen Y-A, Johnson B, Feiler H, et al. [Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancers](/publications/longitudinal-and-multimodal-auditing-tumor-adaptation-cdk46-inhibitors-hr). bioRxiv. 2023:2023–09. Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, et al. [Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer](/publications/endocrine-therapy-synergizes-smac-mimetics-potentiate-antigen-presentation). Cancer Research. 2023;83(19):3284–3304. Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, et al. [Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer](/publications/endocrine-therapy-synergizes-smac-mimetics-potentiate-antigen-presentation). Cancer Research. 2023;83(19):3284–3304. - Previous page chevron\_left - [1](?page=0 "Current page") - [2](?page=1 "Go to page 2") - [3](?page=2 "Go to page 3") - [ Last page 11 ](?page=10 "Go to last page") - [ Next page chevron\_right ](?page=1 "Go to next page")